Evidence map›Paper›PMID 39598384›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases

Yael Schlichter Kadosh, Noa Goorevitch, Kerem Teralı, Jacob Gopas, Ariel Kushmaro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yael Schlichter KadoshAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.ORCID 0009-0001-3389-8764
Noa GoorevitchAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
Kerem TeralıDepartment of Medical Biochemistry, Faculty of Medicine, Cyprus Health and Social Sciences University, Morphou 99750, Cyprus.ORCID 0000-0002-9964-6383
Jacob GopasDepartment of Microbiology, Immunology and Genetics Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.ORCID 0000-0001-9289-8898
Ariel KushmaroAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.ORCID 0000-0002-1970-9656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe repurposing of approved drugs for new activities is gaining widespread attention, including drugs that have antibacterial properties. Nevertheless, besides the benefits of repurposing drugs, the discovery of new antibiotic activity in commonly used medicines raises concerns about inducing antibiotic tolerance and resistance due to the stress produced by the drugs. We found that nebivolol, which is used to treat hypertension, also has antibacterial activity.

methodsThe antibacterial activity of nebivolol was tested by disc diffusion and kinetic O.D. MEASUREMENTS: Antibiofilm activity was determined by crystal violet staining.

resultsNebivolol has antibiotic and antibiofilm activity against several bacteria. However, its effect on

conclusionsNebivolol has antibiotic activity against several bacteria tested but is less effective and possibly detrimental in

Indexed as

antibacterial resistancebiofilmFDA-approved drugnebivololPseudomonas aeruginosa

Identifiers

PMID39598384
PMCPMC11597176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.